Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Emerging Strategies in Hemophilia: Restoring the Homeostatic Balance
  • CME

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: September 26, 2022 Expiration: September 25, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Novo Nordisk Inc.
Guy A. Young, MD
Program Director
Glaivy Batsuli, MD
Allison Wheeler, MD, MSCI

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the engineered mechanism by which new therapies for hemophilia A and B can restore hemostatic balance
  • Evaluate the available data for investigational hemophilia agents and their ability to improve patient outcomes without introducing new health risks
  • Identify patients with hemophilia A or B who may be eligible for enrollment on a clinical trial investigating agents that target anticoagulant pathways or next-generation bispecific antibodies
  • Integrate hemophilia therapies that aim to restore hemostatic balance into clinical practice as they become available

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Guy A. Young, MD

Professor of Pediatrics
Director,
Hemostasis and Thrombosis Center
Children's Hospital Los Angeles
University of Southern California Keck School of Medicine
Los Angeles, California

Guy A. Young, MD: consultant/advisor/speaker: BioMarin, Genentech/Roche, Grifols, Novo Nordisk, Pfizer, Sanofi, Spark, Takeda.

Faculty

Glaivy Batsuli, MD

Assistant Professor of Pediatrics
Pediatric Hematologist
Division of Pediatric Hematology and Oncology
Department of Pediatrics
Emory University
Pediatric Hematologist
Pediatric Hematology and Oncology
Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta
Atlanta, Georgia

Glaivy Batsuli, MD: independent contractor: for Bio Products Laboratories, Kedrion
Allison Wheeler, MD, MSCI

Associate Professor
Department of Pathology, Microbiology, and Immunology
Department of Pediatrics
Vanderbilt University Medical Center
Nashville, Tennessee

Allison Wheeler, MD, MSCI: consultant/advisor/speaker: Bayer, Bioverativ, Novo Nordisk, Sanofi, Spark, Takeda.

Staff

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant financial relationships to disclose.
Nathan Beach, PhD

Editorial Contributor

Nathan Beach, PhD, has no relevant financial relationships to disclose.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant financial relationships to disclose.
Timothy A. Quill, PhD

Vice President, Scientific Services

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.
Krista Marcello

Senior Director, Educational Strategy
Hematology and Oncology

Krista Marcello has no relevant financial relationships to disclose.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for hematologists and other healthcare professionals who care for patients with hemophilia A and B.

Goal

The goal of this activity is to improve the knowledge, competence, and performance of learners in using new and emerging therapeutic options for patients with hemophilia A and B.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 26, 2022, through September 25, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Emerging Strategies in Hemophilia: Restoring the Homeostatic Balance
  • CME

Loading...
Watch this on-demand webcast of a live CCO satellite symposium to learn more about recent advances, unmet clinical needs, and the future of hemophilia therapy.
Guy A. Young, MD
Program Director
Glaivy Batsuli, MD
Allison Wheeler, MD, MSCI
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: September 26, 2022 Expiration: September 25, 2023

Related Content

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the expanding treatment options for hemophilia A & B

Stacy Croteau Headshot Stacy E. Croteau, MD, MMS
Program Director
Guy A. Young, MD
Program Director
Released: January 25, 2023

Data on JAK2 V617F molecular response from a study of ruxolitinib in patients with polycythemia vera or essential thrombocythemia, from ASH 2022 and reported by Clinical Care Options (CCO)

Released: December 19, 2022

New data from APPLY-PNH study of iptacopan in patients with paroxysmal nocturnal hemoglobinuria, presented at ASH 2022 and reported by Clinical Care Options (CCO)

Released: December 17, 2022

Results from phase II trial of second-in-class oral factor D inhibitor vemircopan in previously untreated patients with PNH, presented at ASH 2022 and reported by Clinical Care Options( CCO)

Released: December 16, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Novo Nordisk Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings